Routine WT1 Antibody Screen Uncovers an Exciting New Cancer-Cleaning Enzyme

Enzyme antibodies are widely used in both apoptosis and cancer studies, as disruption of the proteins regulating apoptosis is known to lead to formation of tumor cells in certain cancers. We at Novus Biologicals are continually growing our enzyme antibody database offerings.

Recently, a seemingly basic antibody study into the mechanism of action of WT1 (the Wilms tumour oncogene) revealed that the protease HtrA2 may have a hitherto unknown role as a 'cell cleaning' enzyme, able to eradicate WT1, thus preventing development of cancer. The Wilms tumor is an embryonic cancer identified by mutation of WT1, a transcription protein that normally acts as a tumor suppressor during kidney development. WT1 has several transcript variants and can cleave in several ways to bind to other cellular factors. It is expressed at high levels in a number of childhood and adult cancers, including myeloid leukaemia, and breast and lung tumors.

Immunohistochemistry-Paraffin: Wilms Tumor 1 Antibody

WT1 has been extensively studied, although its role in the development of non-Wilms cancers is poorly understood. We at Novus Biologicals have a large number of WT1 products in our antibody catalog, allowing researchers to delve into binding mechanisms at WT1 domain sites. It was while conducting such a trial that Doctors Joerg Hartkamp and Stefan Roberts, of Manchester University, discovered the cell-cleaning attributes of HtrA2. Previously known only to play a role in programmed cell death, it was found to remove WT1 from cancer cells. HtrA2 antibody research has been conducted as far back as 1996. This exciting news proves there is always something new to be found, on even the oldest antibody database.

Novus Biologicals offers many Wilms Tumor 1 reagents for your research needs including:

• Wilms Tumor 1 Antibodies
• Wilms Tumor 1 Lysates
• Wilms Tumor 1 RNAi
• Wilms Tumor 1 Peptides and Proteins